Current Treatment Options in Gastroenterology

, Volume 8, Issue 6, pp 433–441 | Cite as

Management of chronic Hepatitis C virus in patients with HIV

  • Stephanie A. Santos
  • Nickolas Kontorinis
  • Douglas T. Dieterich

Opinion statement

The life expectancy of HIV seropositive persons is approaching the life expectancy of those who are uninfected with HIV. Hepatitis C virus (HCV) infection has emerged as a worldwide epidemic. Given the similar transmission route between HCV and HIV, there has been an explosion in the number of individuals infected with both viruses. Because of the successful introduction of antiretroviral therapy, patients are more susceptible to new opportunistic infections such as HCV. HCV leads to a more rapid progression to end-stage liver disease in patients with HIV, and the morbidity and mortality related to HCV in co-infected patients is on the rise. Therefore, it has become imperative to treat both HIV and HCV in co-infected patients. The primary goal of HCV therapy is permanent eradication of the virus. Secondary goals include reduction in hepatic fibrosis progression, development of decompensated cirrhosis, and hepatocellular carcinoma. Early studies using standard interferon-alfa for the treatment of HCV in co-infected individuals were discouraging, as poor outcomes, high discontinuation rates, and severe adverse events were observed. The current standard of care for treatment of HCV is pegylated-interferon and ribavirin. New studies have recently demonstrated a higher sustained virologic response rate and a better adverse event profile than previously reported in co-infected patients. As a result, we recommend considering all co-infected patients for HCV therapy while watching closely for unique treatment-related toxicities. The treatment of HCV in co-infected patients should be a high priority for all providers.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Alter MJ, Kruszon-Moran D, Nainan OV, et al.: The prevalence of hepatitis C virus infection in the United States, 1988–1994. N Engl J Med 1999, 351: 556–562.CrossRefGoogle Scholar
  2. 2.
    Sherman KE, Rouster SD, Chung RT, Rajicic N: Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group. Clin Infect Dis 2002, 34: 831–837.PubMedCrossRefGoogle Scholar
  3. 3.
    Sulkowski MS, Thomas DL: Hepatitis C in the HIVInfected Person. Ann Intern Med 2003, 138: 197–207.PubMedGoogle Scholar
  4. 4.
    Poynard T, Ratziu V, Charlotte F, et al.: Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol 2001, 34: 730–739.PubMedCrossRefGoogle Scholar
  5. 5.
    Puoti M, Spinetti A, Ghezzi A, et al.: Mortality for liver disease in patients with HIV infection: a cohort study. J Acquir Immune Defic Syndr 2000, 24: 211–217.PubMedGoogle Scholar
  6. 6.
    Bonacini M, Govindarajan S, Blatt LM, et al.: Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999, 6: 203–208.PubMedCrossRefGoogle Scholar
  7. 7.
    Eyster ME, Fried MW, Di Bisceglie AM, Goedert JJ: Increasing hepatitis C virus RNA levels in hemophiliacs: relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood 1994, 84: 1020–1023.PubMedGoogle Scholar
  8. 8.
    Benhamou Y, Bochet M, Di Martino V, et al.: Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The MULTIVIR Group. Hepatology 1999, 30: 1054–1058.PubMedCrossRefGoogle Scholar
  9. 9.
    Wit FW, Weverling GJ, Weel J, et al.: Incidence of and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002, 186: 23–31.PubMedCrossRefGoogle Scholar
  10. 10.
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD: Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000, 283: 74–80.PubMedCrossRefGoogle Scholar
  11. 11.
    Kontorinis N, Dieterich D: Hepatotoxicity of antiretroviral therapy. AIDS Rev 2003, 5: 36–43.PubMedGoogle Scholar
  12. 12.
    Kontorinis N, Dieterich DT: Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Semin Liver Dis 2003, 23: 173–182.PubMedCrossRefGoogle Scholar
  13. 13.
    Carr A: HIV protease inhibitor-related lipodystrophy syndrome. Clin Infect Dis 2000, 30(Suppl 2): S135-S142.PubMedCrossRefGoogle Scholar
  14. 14.
    Pineda JA, Romero-Gomez M, Diaz-Garcia F, et al.: HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005, 41: 779–789.PubMedCrossRefGoogle Scholar
  15. 15.
    Benhamou Y, Di Martino V, Bochet M, et al.: Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy. Hepatology 2001, 34: 283–287.PubMedCrossRefGoogle Scholar
  16. 16.
    Qurish N, Kreuzberg C, Luchters G, et al.: Effect of antiretroviral therapy on liver-related mortality in liverrelated mortality in patients with HIV and hepatitis C virus coinfection. Lancet 2003, 362: 1708–1713.CrossRefGoogle Scholar
  17. 17.
    Mehta SH, Thomas DL, Torbenson M, et al.: The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005, 41: 123–131.PubMedCrossRefGoogle Scholar
  18. 18.
    Greub GLB, Lederberger B, Battegay M, et al.: Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: the Swiss HIV Cohort Study. Lancet 2000, 356: 1800–1805.PubMedCrossRefGoogle Scholar
  19. 19.
    Sulkowski MS, Moore RD, Mehta SH, et al.: Hepatitis C and progression of HIV disease. JAMA 2002, 288: 199–206.PubMedCrossRefGoogle Scholar
  20. 20.
    McHutchison JG, Gordon SC, Schiff ER, et al.: Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339: 1485–1492.PubMedCrossRefGoogle Scholar
  21. 21.
    Manns MP, McHutchison JG, Gordon SC, et al.: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358: 958–965.PubMedCrossRefGoogle Scholar
  22. 22.
    McHutchison JG, Fried MW: Current therapy for hepatitis C: pegylated interferon and ribavirin. Clin Liver Dis 2003, 7: 149–161.PubMedCrossRefGoogle Scholar
  23. 23.
    FriedM, Shiffman M, Reddy R, et al.: Peginterferon alfa-2b plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347: 975–983. This paper showed the SVR among different genotypes for the current standard of care of hepatitis C treatment.PubMedCrossRefGoogle Scholar
  24. 24.
    Muir AJ, Bornstein JD, Killenberg PG: Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-hispanic whites. N Engl J Med 2004, 350: 2265–2271.PubMedCrossRefGoogle Scholar
  25. 25.
    Jeffers LJ, Cassidy W, Howell CD, et al.: Peginterferon alfa-2a (40kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004, 39: 1702–1778.PubMedCrossRefGoogle Scholar
  26. 26.
    Kaplan JE, Masur H, Holmes KK: Guidelines for preventing opportunistic infections among HIV infected persons. Morb Mortal Wkly Rep 2002, 51: 1–46.Google Scholar
  27. 27.
    Soriano V, Sulkowski M, Bergin C, et al.: Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002, 16: 813–828.PubMedCrossRefGoogle Scholar
  28. 28.
    Romero M, Perez-Olmeda M, Garcia-Samaniego J, Soriano V: Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations. Drug Saf 2004, 27: 7–24.PubMedCrossRefGoogle Scholar
  29. 29.
    Sulkowski M, Felizarta F, Smith C, et al.: Daily versus thrice-weekly interferon Alfa-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected persons: a multicenter randomized controlled trial. J Acquir Immune Defic Syndr 2004, 35: 464–472.PubMedCrossRefGoogle Scholar
  30. 30.
    Neau D, Trimoulet P, Winnock M, et al.: Comparison of 2 regimens that include interferon-alfa-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003, 36: 1564–1571.PubMedCrossRefGoogle Scholar
  31. 31.
    Chung R, Andersen J, Volberding P, et al.: Peginterferon alfa-2a plus ribavirin vs interferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVco-infected persons. N Engl J Med 2004, 351: 451–459.PubMedCrossRefGoogle Scholar
  32. 32.
    Perronne C, Carrat F, Bani-Sadr F, et al.: Final results of ANRS HC02-RIBAVIC: A randomized controlled trial of pegylated-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV co-infected patients [abstract 117LB]. Eleventh Conference on Retroviruses and Opportunistic Infections. San Fransisco, CA; February, 2004.Google Scholar
  33. 33.
    TorrianiFJ, Rodriguez-Torres M, Rockstroh et al.: Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004, 351: 438–450. This study is the largest to date and demonstrates the highest SVR for co-infected patients.PubMedCrossRefGoogle Scholar
  34. 34.
    Perez-Olmeda M, Nunez M, Romero M, et al.: Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17: 1023–1028.PubMedCrossRefGoogle Scholar
  35. 35.
    Levitan SA, Uriel A, Kontorinis N, Dieterich DT: Use of dronabinol for treatment of common side effects of chronic hepatitis C therapy. Gastro 2004, 126(Suppl 2): A-723.Google Scholar
  36. 36.
    Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with anti-retroviral therapy for HIV-1 infection: recommendations of an international AIDS society-USA panel. J Acquir Immune Defic Syndr 2002, 31: 257–275.PubMedGoogle Scholar
  37. 37.
    Ohnishi K, Matsuo S, Matsutani K, et al.: Interferon therapy for chronic hepatitis C in habitual drinkers: comparison with chronic hepatitis C in infrequent drinkers. Am J Gastroenterol 1996, 91: 1374–1379.PubMedGoogle Scholar
  38. 38.
    Davis GL, Rodrigue JR: Treatment of chronic hepatitis C in active drug users. N Engl J Med 2001, 345: 215–217.PubMedCrossRefGoogle Scholar
  39. 39.
    Castera L, Zigante F, Bastie A, et al.: Incidence of interferon alfa-induced depression in patients with chronic hepatitis C. Hepatology 2002, 35: 978–979.PubMedCrossRefGoogle Scholar
  40. 40.
    Farah A: Interferon-induced depression treated with citalopram. J Clin Psychiatry 2002, 63: 166–167.PubMedGoogle Scholar
  41. 41.
    Braun M, Vierling JM: The clinical and immunologic impact of using interferon and ribavirin in the immunosuppressed host. Liver Transpl 2003, 9: S79-S89.PubMedCrossRefGoogle Scholar
  42. 42.
    Janssen HLA, Brouwer JF, van der Mase RC, et al.: Suicide associated with alpha-interferon therapy for chronic viral hepatitis. J Hepatol 1994, 21: 241–243.PubMedCrossRefGoogle Scholar
  43. 43.
    Fontaine H, Pol S: Side effects of interferon-alfa in treating hepatitis C virus infection. Transplant Proc 2001, 33: 2327–2329.PubMedCrossRefGoogle Scholar
  44. 44.
    Dieterich DT, Wasserman R, Brau N, et al.: Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol 2003, 98: 2491–2499.PubMedGoogle Scholar
  45. 45.
    McHutchison JG: Hepatitis C advances in antiviral therapy: what is accepted treatment now? J Gastroenterol Hepatol 2002, 17: 431–441.PubMedCrossRefGoogle Scholar
  46. 46.
    Mauss S, Valenti W, DePamphilis J, et al.: Risk factors for hepatic decompensation in patients with HIC/ HCV coinfection and liver cirrhosis during interferonbased therapy. AIDS 2004, 18: F21-F25.PubMedCrossRefGoogle Scholar
  47. 47.
    Sulkowski MS: Anemia in the treatment of hepatitis C virus infection. Clin Infect Dis 2003, 37(Suppl 4): S315-S322.PubMedCrossRefGoogle Scholar
  48. 48.
    Sood ARN, Russo MW, et al.: Use of granulocyte colony stimulating factor (GCSF) for interferon induced neutropenia in patients with chronic hepatitis C infection [abstract 1029]. Program and abstracts of the 52nd annual meeting of the AASLD (Dallas, TX). Alexandria: AASLD; 2001: 429A.Google Scholar
  49. 49.
    Patel K, Dev A, Muir AJ, McHutchison JG: Ribavirin as maintenance therapy for hepatitis C patients: an interim peacekeeper? Hepatology 2003, 38: 21–24.PubMedCrossRefGoogle Scholar
  50. 50.
    Lafeuillade A, Hittlinger G, Chadapaud S: Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet 2001, 357: 280–281.PubMedCrossRefGoogle Scholar
  51. 51.
    Landau A, Batisse D, Piketty C, et al.: Lack of interference between ribavirin and nucleoside analogues in HIV/HCV coinfected individuals undergoing concomitant anti-retroviral and anti-HCV combination therapy. AIDS 2000, 14: 1857–1858.PubMedCrossRefGoogle Scholar
  52. 52.
    Henessy M, Mulcahy F, Spiers P, et al.: Differential effects of combined pegylated interferon and ribavirin therapy on intracellular nucleotide triphosphate levels in HIV/HCV co-infected patients, a potential mechanism for enhanced toxicity [abstract 822]. Eleventh Conference on Retroviruses and Opportunitic Infections. San Francisco, CA; February, 2004.Google Scholar
  53. 53.
    De Franceschi L, Fattovich G, Turrini F, et al.: Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000, 31: 997–1004.PubMedCrossRefGoogle Scholar
  54. 54.
    Rendon AL, Nunez M, Romero M, et al.: Early monitoring of Ribavirin plasma concentrations may predict anemia and early virologic response in HIV/Hepatitis C virus-coinfected patients. JAIDS 2005, 39: 401–405.PubMedGoogle Scholar
  55. 55.
    Sulkowski M, Dieterich DT, Bini E, et al.: Epoetin-alfa administered once weekly improves anemia in HIV/ HCV co-infected patients treated with interferon/ ribavirin therapy: a randomized controlled trial. JAIDS 2005, 39: 504–506. This paper demonstrates the major importance of using epoetin-alfa for the anemia frequently seen associated with interferon and ribavirin therapy.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2005

Authors and Affiliations

  • Stephanie A. Santos
  • Nickolas Kontorinis
  • Douglas T. Dieterich
    • 1
  1. 1.Department of MedicineThe Mount Sinai Medical CenterNew YorkUSA

Personalised recommendations